Because our previous studies suggested that use of insulin [22, 23] and/or sulfonylurea [24] are associated with a significantly higher risk of breast cancer, the higher proportions of their use in ever users of rosiglitazone (Table 1) might have only underestimated the beneficial effect of rosiglitazone. The gene discussed is INS; the disease is breast carcinoma.